Selective Vaccines


In February of 2014 the ACIP approved the 9-valent HPV (9vHPV) vaccine in addition to the two HPV vaccines previously used (2vHPV and 4vHPV). All three vaccines target HPV 16 and 18 which lead to 66% of cervical cancers in the US. Additionally, the 9vHPV targets HPV 31, 33, 45, 52, 58 (which lead to an additional 15% of cervical cancers). 4vHPV and 9vHPV also target HPV 6 and 11 which are responsible for anogenital warts. 

ACIP recommends that a vaccine series started with 2vHPV or 4vHPV be completed with 9vHPV. However, there is no ACIP recommendation for additional 9vHPV vaccination if a 3 dose series was previously completed.6

What to know in clinic:

HPV vaccine does not clear HPV already present

Women should still get cervical cancer screening at age 21

Females: All three vaccines, age 13-26

Males: 4vHPV & 9vHPV, age 13-21 (MSM through age 26)

*Vaccination is permitted in males age 21-26 with no other risks but is not considered routine 

Can be given when immunocompromised, but not pregnant 

Series Timeline: 4vHPV & 9vHPV (0, 2, 6 months), 2vHPV (0, 1, 6 months)



Adult Vaccinations Copyright © by Stacy C. Kramer, MD. All Rights Reserved.

Share This Book